GSK has delivered a solid multi year share price run, helped by fresh moves in oncology and vaccines, and that raises a ...

According to Sharecast on September 18, 2026, Berenberg upgraded GSK from Hold to Buy and lifted its target price on the stock from GBP 20 to GBP 22, arguing that recent business-development ...

GSK stock rose 0.4% after Berenberg upgraded to buy with a £22 target and GSK announced a $750M deal with Chimagen Biosciences for a multiple myeloma asset.

GSK stock increased 0.4% following Berenberg's upgrade to buy with £22 target and announcement of $750M Chimagen deal for multiple myeloma therapy.

GSK stock in London traded around 1,858.5 pence on September 15, 2026 after the company agreed a deal worth up to USD 750 million for a blood cancer drug. Berenberg raised its rating to Buy and lifted ...

The latest installment in BioPharma Dive’s new visualization-focused series features a stock sell-off that confused Wall ...

On Monday, GSK plc GSK stock is trading higher on highly positive clinical data from two separate lung cancer trials, ...

India, Sept. 14 -- UK Stock Market Today (September 14, 2026): The FTSE 100 is trading higher today on September 14, 2026 on ...

GSK PLC GSK +1.87% shares rose 4.74% to £18.55 Monday, on what proved to be an all-around positive trading session for the stock market, with the FTSE 100 Index UKX -0.28% rising 0.44% to 10,697.57.

Tempus AI (TEM) stock surged 15% Thursday as CEO outlined up to $400M in Medicare revenue. TEM is up 92% from its July low.

Berenberg upgrades GSK to Buy, raises target to £22, cites pipeline catalysts and cost cuts supporting margins and growth. Read more here.

GSK (GSK) agreed to acquire global rights to an experimental T-cell engager therapy for multiple myeloma from Chinese biotechnology company Chimagen Biosciences in a deal worth up to $750 million, as ...